608 related articles for article (PubMed ID: 32087678)
21. A Rapid and Simple UHPLC-MS/MS Method for Quantification of Plasma Globotriaosylsphingosine (lyso-Gb3).
Perrone A; Mohamed S; Donadio V; Liguori R; Contin M
Molecules; 2021 Dec; 26(23):. PubMed ID: 34885938
[TBL] [Abstract][Full Text] [Related]
22. Phenotypical characterization of α-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young.
De Brabander I; Yperzeele L; Ceuterick-De Groote C; Brouns R; Baker R; Belachew S; Delbecq J; De Keulenaer G; Dethy S; Eyskens F; Fumal A; Hemelsoet D; Hughes D; Jeangette S; Nuytten D; Redondo P; Sadzot B; Sindic C; Sheorajpanday R; Thijs V; Van Broeckhoven C; De Deyn PP
Clin Neurol Neurosurg; 2013 Jul; 115(7):1088-93. PubMed ID: 23219219
[TBL] [Abstract][Full Text] [Related]
23. Screening of Fabry disease in patients with chronic kidney disease in Japan.
Nagata A; Nasu M; Kaida Y; Nakayama Y; Kurokawa Y; Nakamura N; Shibata R; Hazama T; Tsukimura T; Togawa T; Saito S; Sakuraba H; Fukami K
Nephrol Dial Transplant; 2021 Dec; 37(1):115-125. PubMed ID: 34282462
[TBL] [Abstract][Full Text] [Related]
24. Results of Fabry Disease Screening in Male Pre-End Stage Renal Disease Patients with Unknown Etiology Found Through the Platform of a Chronic Kidney Disease Education Program in a Northern Taiwan Medical Center.
Lin CJ; Chien YH; Lai TS; Shih HM; Chen YC; Pan CF; Chen HH; Hwu WL; Wu CJ
Kidney Blood Press Res; 2018; 43(5):1636-1645. PubMed ID: 30380558
[TBL] [Abstract][Full Text] [Related]
25. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
Togawa T; Kodama T; Suzuki T; Sugawara K; Tsukimura T; Ohashi T; Ishige N; Suzuki K; Kitagawa T; Sakuraba H
Mol Genet Metab; 2010 Jul; 100(3):257-61. PubMed ID: 20409739
[TBL] [Abstract][Full Text] [Related]
26. Targeted Screening of Fabry Disease in Male Hemodialysis Patients in Brazil Highlights Importance of Family Screening.
Silva CA; Barreto FC; Dos Reis MA; Moura Junior JA; Cruz CM
Nephron; 2016; 134(4):221-230. PubMed ID: 27576502
[TBL] [Abstract][Full Text] [Related]
27. Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes.
Nowak A; Mechtler TP; Desnick RJ; Kasper DC
Mol Genet Metab; 2017; 120(1-2):57-61. PubMed ID: 27773586
[TBL] [Abstract][Full Text] [Related]
28. Systematic gene therapy derived from an investigative study of AAV2/8 vector gene therapy for Fabry disease.
Deng M; Zhou H; He S; Qiu H; Wang Y; Zhao AY; Mu Y; Li F; Zhao AZ
Orphanet J Rare Dis; 2023 Sep; 18(1):275. PubMed ID: 37670350
[TBL] [Abstract][Full Text] [Related]
29. Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma.
Ferreira S; Auray-Blais C; Boutin M; Lavoie P; Nunes JP; Martins E; Garman S; Oliveira JP
Clin Chim Acta; 2015 Jul; 447():96-104. PubMed ID: 26070511
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis.
Maruyama H; Miyata K; Mikame M; Taguchi A; Guili C; Shimura M; Murayama K; Inoue T; Yamamoto S; Sugimura K; Tamita K; Kawasaki T; Kajihara J; Onishi A; Sugiyama H; Sakai T; Murata I; Oda T; Toyoda S; Hanawa K; Fujimura T; Ura S; Matsumura M; Takano H; Yamashita S; Matsukura G; Tazawa R; Shiga T; Ebato M; Satoh H; Ishii S
Genet Med; 2019 Jan; 21(1):44-52. PubMed ID: 29543226
[TBL] [Abstract][Full Text] [Related]
31. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
32. Defective lysosomal storage in Fabry disease modifies mitochondrial structure, metabolism and turnover in renal epithelial cells.
Schumann A; Schaller K; Belche V; Cybulla M; Grünert SC; Moers N; Sass JO; Kaech A; Hannibal L; Spiekerkoetter U
J Inherit Metab Dis; 2021 Jul; 44(4):1039-1050. PubMed ID: 33661535
[TBL] [Abstract][Full Text] [Related]
33. Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients.
Rosa Neto NS; Bento JCB; Pereira RMR
Adv Rheumatol; 2020 Jan; 60(1):7. PubMed ID: 31907047
[TBL] [Abstract][Full Text] [Related]
34. Analysis of lyso-globotriaosylsphingosine in dried blood spots.
Johnson B; Mascher H; Mascher D; Legnini E; Hung CY; Dajnoki A; Chien YH; Maródi L; Hwu WL; Bodamer OA
Ann Lab Med; 2013 Jul; 33(4):274-8. PubMed ID: 23826564
[TBL] [Abstract][Full Text] [Related]
35. Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease.
Nowak A; Mechtler TP; Hornemann T; Gawinecka J; Theswet E; Hilz MJ; Kasper DC
Mol Genet Metab; 2018 Feb; 123(2):148-153. PubMed ID: 28728877
[TBL] [Abstract][Full Text] [Related]
36. Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease.
Nowak A; Beuschlein F; Sivasubramaniam V; Kasper D; Warnock DG
J Med Genet; 2022 Mar; 59(3):287-293. PubMed ID: 33495303
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of Fabry disease and GLA variants in young patients with acute stroke: The challenge to widen the screening. The Fabry-Stroke Italian Registry.
Romani I; Sarti C; Nencini P; Pracucci G; Zedde M; Cianci V; Nucera A; Moller J; Orsucci D; Toni D; Palumbo P; Casella C; Pinto V; Barbarini L; Bella R; Scoditti U; Ragno M; Mezzapesa DM; Tassi R; Volpi G; Diomedi M; Bigliardi G; Cavallini AM; Chiti A; Ricci S; Cecconi E; Linoli G; Sacco S; Rasura M; Giordano A; Bonetti B; Melis M; Cariddi LP; Dossi RC; Grisendi I; Aguglia U; Di Ruzza MR; Melis M; Sbardella E; Vista M; Valenti R; Musolino RF; Passarella B; Direnzo V; Pennisi G; Genovese A; Di Marzio F; Sgobio R; Acampa M; Nannucci S; Dagostino F; Dell'Acqua ML; Cuzzoni MG; Picchioni A; Calchetti B; Notturno F; Di Lisi F; Forlivesi S; Delodovici ML; Buechner SC; Biagini S; Accavone D; Manna R; Morrone A; Inzitari D
J Neurol Sci; 2024 Feb; 457():122905. PubMed ID: 38295534
[TBL] [Abstract][Full Text] [Related]
38. The clinical utility of total concentration of urinary globotriaosylsphingosine plus its analogues in the diagnosis of Fabry disease.
Alharbi FJ; Baig S; Rambhatla SB; Vijapurapu R; Auray-Blais C; Boutin M; Steeds R; Wheeldon N; Dawson C; Geberhiwot T
Clin Chim Acta; 2020 Jan; 500():120-127. PubMed ID: 31654629
[TBL] [Abstract][Full Text] [Related]
39. Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease.
Smid BE; van der Tol L; Biegstraaten M; Linthorst GE; Hollak CE; Poorthuis BJ
J Med Genet; 2015 Apr; 52(4):262-8. PubMed ID: 25596309
[TBL] [Abstract][Full Text] [Related]
40. Is just enzyme replacement therapy enough for Fabry disease treatment? Have we missed a trick?
Ozer H; Baloglu I; Topkac A; Ozturk Y; Yonet F; Daglı F; Kilinc İ; Turkmen K
Nefrologia (Engl Ed); 2024; 44(2):217-223. PubMed ID: 37179210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
